Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Massachusetts Convention Center Carpark Wins 2026 IPMI Apex Award
WATERTOWN, Massachusetts, June 15 [Category: BizEngineering] -- Vanasse Hangen Brustlin Inc., a provider of transportation planning, engineering, design, land development and environmental services, posted the following news:
* * *
Massachusetts Convention Center Carpark Wins 2026 IPMI Apex Award
*
The International Parking and Mobility Institute (IPMI) recently honored the Massachusetts Convention Center Carpark with an Apex Award for Architectural Design, which recognizes projects that elevate the industry and deliver unique solutions to complex challenges.
The Massachusetts Convention
... Show Full Article
WATERTOWN, Massachusetts, June 15 [Category: BizEngineering] -- Vanasse Hangen Brustlin Inc., a provider of transportation planning, engineering, design, land development and environmental services, posted the following news:
* * *
Massachusetts Convention Center Carpark Wins 2026 IPMI Apex Award
*
The International Parking and Mobility Institute (IPMI) recently honored the Massachusetts Convention Center Carpark with an Apex Award for Architectural Design, which recognizes projects that elevate the industry and deliver unique solutions to complex challenges.
The Massachusetts ConventionCenter Carpark-located adjacent to the MassMutual Center in Springfield, MA-replaced a deteriorated garage built more than 50 years ago that was operating at only 70 percent capacity. VHB collaborated with key stakeholders from the City of Springfield, the Massachusetts Convention Center Authority (MCCA), and design firm Desman Associates to demolish and replace the garage with an updated, future-ready design.
VHB designed the exterior improvements to the garage that addressed accessibility deficiencies and modified sidewalks outside the facility to comply with the Americans with Disabilities Act (ADA) standards. To facilitate construction, our team provided traffic management services and recommendations throughout the building phase.
The new, state-of-the-art parking facility is five stories, 350,000 square feet, and comprises 817 parking spaces with sustainability features such as EV infrastructure and charging stations. Enhancing the visitor experience, the forward-looking development will provide easy access to the MassMutual Center. In addition, retail and restaurant space on the first level of the garage will activate foot traffic and invigorate the community at large.
VHB also worked extensively on a vibrant, multi-use plaza adjacent to the garage known as "The Landing." Located on Bruce Landon Way, the new area features 12,900 square feet of open-air, multipurpose space, prime for hosting community events, receptions, concerts, and more. In tandem with the new carpark, The Landing will continue to drive economic growth, enhance walkability, and accentuate the hospitality and tourism industry in Western Massachusetts.
"We're proud to have been a part of this impactful project that will stimulate the local economy, enhance the visitor experience for MassMutual Center patrons, and benefit neighborhood residents," said Springfield Land Development Team Leader Michael Petrin.
Discover how VHB's Land Development team delivers every project with precision, efficiency, and a keen focus on maximizing value.
***
Original text here: https://www.vhb.com/news/ma-convention-center-carpark-ipmi-award/
Evan Miller Shares Insights on Senior Housing Design Trends
WATERTOWN, Massachusetts, June 15 [Category: BizEngineering] -- Vanasse Hangen Brustlin Inc., a provider of transportation planning, engineering, design, land development and environmental services, posted the following news:
* * *
Evan Miller Shares Insights on Senior Housing Design Trends
*
Last week, Senior Project Manager Evan Miller joined panelists at BisNow's Northeast Senior Housing Conference to discuss the future of senior housing. The event brought together investors, policymakers, and developers from across the region to explore rising occupancy, limited housing supply, sustainability
... Show Full Article
WATERTOWN, Massachusetts, June 15 [Category: BizEngineering] -- Vanasse Hangen Brustlin Inc., a provider of transportation planning, engineering, design, land development and environmental services, posted the following news:
* * *
Evan Miller Shares Insights on Senior Housing Design Trends
*
Last week, Senior Project Manager Evan Miller joined panelists at BisNow's Northeast Senior Housing Conference to discuss the future of senior housing. The event brought together investors, policymakers, and developers from across the region to explore rising occupancy, limited housing supply, sustainabilityrequirements affecting budgets and approvals, and the unit types and care models that are attracting the most investment.
As VHB's Residential Market Lead, Evan advises our developer partners in creating well designed, permittable, and cost-effective projects. With more than two decades of landscape architecture and design experience, Evan was invited to speak on the panel "Building and Designing Senior Housing Facilities," where he shared insights on the programming innovations, design shifts, and sustainability upgrades that are reshaping senior housing. He also addressed how Massachusetts' proposed rent control ballot could impact future development decisions, how wellness is increasingly being integrated as a design philosophy rather than a standalone amenity, and how senior housing developers are balancing rising construction costs with resident's affordability.
"Shifting demographics, regulatory complexities, and market expectations are all affecting the senior housing sector," said Evan. "VHB helps clients navigate those changes through local knowledge, strong agency relationships, and integrated planning and design."
VHB is actively partnering with developers on senior housing throughout the East Coast that support independence, connectivity, and active lifestyles. Examples include:
The Newbury at Brookline | Brookline, MA
VHB provided transportation planning and engineering services to support the repositioning of the former Newbury College campus to an award-winning senior living community. Our team drew on long-standing relationships with the Town of Brookline to help the development team, municipal leaders, and neighbors understand and manage transportation impacts stemming from the redevelopment
Evergreen Crossings | South Windsor, CT
Through close coordination with the architect, client, and local agencies, VHB developed the site plan and supporting infrastructure for this 125-room independent retirement community. The resulting context-sensitive design supports resident mobility, addresses traffic and parking needs, and contributes to a high-quality senior living environment.
Helen Porter Rehabilitation and Nursing Courtyard | Middlebury, VT
Our landscape architecture team planned and designed a therapeutic memory care courtyard for this center that expands opportunities for safe outdoor time and meaningful connection. The space supports resident well-being while creating a welcoming, restorative environment for families and staff.
Discover how VHB helps senior living providers create communities that provide a full continuum of care-from independent and assisting living to memory care, skilled nursing, and rehabilitation.
***
Original text here: https://www.vhb.com/news/evan-miller-bisnow-senior-housing-conference/
Nexstar Media Foundation Announces Honorees for Day Fourteen of "30 Days of Giving" Initiative
IRVING, Texas, June 14 [Category: BizMedia] -- Nexstar Media Group, a television broadcasting company, issued the following news release:
* * *
Nexstar Media Foundation Announces Honorees for Day Fourteen of "30 Days of Giving" Initiative
*
Urban Baby Beginnings and Sleep in Heavenly Peace-Savannah Named as Recipients of $5,000 Grants
Irving, TX (June 14, 2026) - Nexstar Media Group, Inc. (NASDAQ: NXST), today announced that the Nexstar Media Charitable Foundation is making a $5,000 contribution to both Urban Baby Beginnings and Sleep in Heavenly Peace-Savannah as part of the company's "30
... Show Full Article
IRVING, Texas, June 14 [Category: BizMedia] -- Nexstar Media Group, a television broadcasting company, issued the following news release:
* * *
Nexstar Media Foundation Announces Honorees for Day Fourteen of "30 Days of Giving" Initiative
*
Urban Baby Beginnings and Sleep in Heavenly Peace-Savannah Named as Recipients of $5,000 Grants
Irving, TX (June 14, 2026) - Nexstar Media Group, Inc. (NASDAQ: NXST), today announced that the Nexstar Media Charitable Foundation is making a $5,000 contribution to both Urban Baby Beginnings and Sleep in Heavenly Peace-Savannah as part of the company's "30Days of Giving" initiative, a month-long program recognizing and supporting nonprofit and charitable organizations serving communities across Nexstar's nationwide footprint.
"30 Days of Giving" is an employee-driven initiative created to celebrate the 30th anniversary of Nexstar's founding in June 1996. Locally-led committees reviewed submissions from Nexstar's 13,000 employees and selected charitable and nonprofit organizations to nominate for grants. More than 100 organizations were nominated, and the Nexstar Charitable Foundation's Board of Directors chose 60 to receive $5,000 each. Every day during the month of June, the Foundation will award two $5,000 grants; by the end of the month the Foundation will have committed $300,000 to "30 Days of Giving."
The Foundation today recognized Urban Baby Beginnings and Sleep in Heavenly Peace-Savannah as recipients of $5,000 grants. The organizations were nominated by employees at WRIC-TV, the Nexstar television station serving Richmond, VA, and WSAV-TV in Savannah, GA, respectively.
Urban Baby Beginnings (UBB) is committed to ensuring every woman of childbearing age has access to high-quality, compassionate, and culturally relevant maternal care. The organization works to reduce adverse outcomes for families during the prenatal, postpartum, and early childhood stages. UBB's hubs in Richmond, Norfolk, Newport News, Petersburg, and Roanoke, as well as a telehealth platform, connect families with hospitals, providers, and community-based organizations to ensure care is accessible and the medical and social needs of families are met. UBB's participating families experience reduced stress and isolation, improved outcomes in breastfeeding, postpartum recovery, and newborn health, and receive essential resources such as diapers, nutrition, and safe sleep education.
"We are honored to support Urban Baby Beginnings through the Nexstar Charitable Foundation's '30 Days of Giving' campaign," said Steve Blanchard, Vice President and General Manager of WRIC-TV in Richmond, VA. "Our employees selected this organization because of the meaningful difference it makes in the lives of families throughout our community. At WRIC, serving our viewers includes not only telling stories that matter, but also supporting organizations that are creating positive change."
To learn more about Urban Baby Beginnings, visit https://urbanbabybeginnings.org/ and to donate, go to https://urbanbabybeginnings.org/donate/.
Sleep in Heavenly Peace (SHP) is the leading national nonprofit dedicated to building and delivering hand-made, fully furnished beds to children in need. With more than 350 chapters across the United States, SHP's works to combat childhood bedlessness, which it estimates to affect nearly 3% of the population.
The organization's Savannah chapter serves families in Savannah, GA, and parts of Garden City within Chatham County, where an estimated 9,000 children sleep on the floor every night. As of May 2026, the chapter has delivered 113 beds this year, each complete with bedding, a pillow, and a twin mattress.
"At WSAV, we believe strong communities are built when neighbors support neighbors," said David Hart, Vice-President and General Manager, WSAV-TV in Savannah, GA. "With that in mind, we are honored to present this $5,000 grant to Sleep in Heavenly Peace on behalf the Nexstar Charitable Foundation, and support their incredible mission of ensuring that every child has a safe, comfortable bed to sleep in.. The work they do has a direct impact on the well-being, safety, and dignity of children and families throughout the Coastal Empire of Southeast Geogia."
For more information on the Savannah chapter of Sleep in Heavenly Peace, visit https://shpbeds.org/chapter/ga-savannah/. To donate, go to https://shpbeds.org/?form=FUNWQMGMTCQ&CId=0014x00001uK8Vm.
The Nexstar Media Charitable Foundation's mission is to contribute to and work with public charities and non-profit organizations to improve the communities in which Nexstar Media and its subsidiaries do business.
About Nexstar Media Group, Inc.
Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that produces and distributes engaging local and national news, sports, and entertainment content across its television and digital platforms. For more information, please visit nexstar.tv.
Media Contact
Gary Weitman
EVP and Chief Communications Officer
Nexstar Media Group, Inc.
(972) 373-8800 or gweitman@nexstar.tv
***
Original text here: https://www.nexstar.tv/nexstar-media-foundation-announces-honorees-for-day-fourteen-of-30-days-of-giving-initiative/
ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma
BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma
*
Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.
In a first-of-its-kind randomized trial, Dana-Farber Cancer Institute researchers
... Show Full Article
BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma
*
Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.
In a first-of-its-kind randomized trial, Dana-Farber Cancer Institute researchersfound that teclistamab may significantly improve outcomes for patients with high-risk smoldering multiple myeloma, a precursor condition that can progress to active cancer. In the phase 2 ImmunoPRISM trial, the BCMA-targeted bispecific antibody outperformed lenalidomide plus dexamethasone, pointing to the potential value of using immune-based therapy earlier in the course of the disease.
The results were presented by Omar Nadeem, MD, Medical Director of the Center of Early Detection and Interception of Blood Cancers at Dana-Farber Cancer Institute, in a late-breaking session at the European Hematology Association Congress in Stockholm, Sweeden, June 11 to 14.
Three-quarters of patients receiving teclistamab (75.6%) achieved a complete response, compared with none in the group who received the combination therapy. Teclistamab also drove exceptionally deep remissions based on highly sensitive testing. Among patients who could be evaluated for minimal residual disease (MRD), a measure of whether cancer cells can still be detected at very low levels, 82% of those in the teclistamab group became MRD-negative. No patients in group that received combination therapy achieved MRD negativity. All MRD-negative responses remained ongoing at the time of the data cutoff.
"These are striking results because this is the first randomized study to show that a BCMA-targeted bispecific therapy can outperform a lenalidomide-based approach in high-risk smoldering myeloma," said Nadeem. "We saw rapid, deep responses, including a high rate of complete responses and MRD negativity, and those responses have remained durable so far. These findings suggest that treating patients earlier -before they develop symptomatic multiple myeloma -may meaningfully change the trajectory of the disease."
About 50 percent of patients with high-risk smoldering multiple myeloma will progress to active multiple myeloma within two years. Current standard of care for high-risk smoldering myeloma is observation, however a combination of lenalidomide plus dexamethasone has been shown in previously clinical trials to delay progression.
Teclistamab, which engages both cancer cells and T cells to redirect T cells to the cancer, is approved for the treatment of relapsed/refractory multiple myeloma. T-cell redirection, however, might be more effective if used earlier in the disease process, before patients are exposed to therapies that can increase the chances of drug resistance, and before they transition into full-blown multiple myeloma, which can compromise immune system function.
ImmunoPRISM enrolled 59 patients with high-risk smoldering multiple myeloma based on established risk criteria. Patients were randomized, with 45 receiving teclistamab and 14 receiving the lenalidomide combination therapy. Beyond complete responses, 87% of patients treated with teclistamab achieved a very good partial response or better, compared with 14% in the combination therapy group.
Teclistamab also significantly improved progression free survival, with 7% of patients in the teclistamab progressing after a median 23.4 months of follow up, compared to 36% in the combination therapy group. An estimated 92 percent of patients will be alive and disease free after two years with teclistamab compared to an estimated 51 percent with the combination therapy.
While 71 percent of patients receiving teclistamab experienced cytokine release syndrome (CRS), a known side effect of some T-cell therapies, all were low grade. No neurological toxicities were observed. Other observed side effects were manageable, and rates of high-grade infections were lower than observed in clinical trials of patients with relapsed/refractory multiple myeloma treated with teclistamab.
"Taken together, these findings provide compelling evidence that early immunologic intervention may be a highly effective strategy for myeloma interception," said Irene Ghobrial, MD, Director of the Center for Early Detection and Interception of Blood Cancers at Dana-Farber. "By harnessing the immune system before the onset of symptomatic disease, teclistamab may leverage preserved immune fitness and lower disease burden to achieve deeper, more durable disease control and potentially prevent progression to active multiple myeloma."
***
Original text here: https://www.dana-farber.org/newsroom/news-releases/2026/immunoprism-trial-shows-teclistamab-improves-depth-of-response-and-progression-free-survival-in-high-risk-smoldering-multiple-myeloma
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
*
A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixed-duration therapy in relapsed/refractory chronic lymphocytic leukemia.
Triplet therapy with pirtobrutinib, venetoclax, and rituximab as a two-year
... Show Full Article
BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
*
A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixed-duration therapy in relapsed/refractory chronic lymphocytic leukemia.
Triplet therapy with pirtobrutinib, venetoclax, and rituximab as a two-yearfixed-duration therapy improves progression free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared to standard of care venetoclax plus rituximab therapy, according to interim data from the randomized, phase 3 BRUIN CLL-322 clinical trial. Matthew Davids, MD, MMSc, Chief of the Division of Lymphoma at Dana-Farber Cancer Institute, presented the results in the Late-Breaking Abstract session at the European Hematology Association 2026 Congress in Stockholm, Sweden, on June 14, 2026.
"When pirtobrutinib is added to the standard venetoclax-rituximab regimen, we see a substantial improvement in progression free survival, even better than we hypothesized," says Davids. "That speaks to the power of the triplet-based therapy over the doublet and supports consideration of the triplet as a new standard of care option for relapsed/refractory CLL."
In the US and in many areas of the world, patients diagnosed with CLL receive a covalent BTK inhibitor, such as ibrutinib, acalabrutinib, or zanubrutinib as standard first-line therapy. Standard second line therapy currently combines venetoclax, a BCL-2 inhibitor developed based in part on science from Dana-Farber laboratories, and rituximab, an immunotherapy targeting CD20, an antigen initially described at Dana-Farber. The combination is given over a fixed duration and has been standard of care for about eight years.
The U.S. Food and Drug Administration granted full approval for pirtobrutinib, a non-covalent BTK inhibitor, in 2025 as single-agent therapy for patients with relapsed/refractory CLL who previously received a covalent BTK inhibitor. Pirtobrutinib given continuously has been found in other studies to be effective and better tolerated than ibrutinib, likely due to its high potency and selectivity.
The randomized, phase 3 BRUIN CLL-322 trial was designed to determine if a time-limited combination of a non-covalent BTK inhibitor pirtobrutinib and a BCL-2 inhibitor, venetoclax, plus immunotherapy with rituximab could deliver deeper, more durable responses in patients with relapsed/refractory CLL compared to standard therapy. The study included 639 patients with relapsed/refractory CLL, most of whom had previously received a covalent BTK inhibitor. Patients were randomized to receive either triplet or doublet therapy for a fixed duration of approximately two years.
At two years, 86.9 percent of patients taking the triplet therapy were still alive and had not progressed compared to 71.8 percent of those taking the doublet, a 45 percent lowered risk of worsening disease or death. Peripheral blood undetectable minimal residual disease MRD rates at end of treatment were higher with the triplet in patients with evaluable samples at 86%, compared to 61% in the doublet. Patients taking the triplet therapy experienced minimal additional side effects and tolerated the therapy well. More follow-up is needed to evaluate overall survival.
"Pirtobrutinib is one of the best tolerated targeted drugs we use in CLL, and when we add it to the standard regimen, we see only small differences in safety profile," says Davids. "Patients are getting this added progression free survival benefit without much added toxicity, suggesting that this triplet therapy can benefit a wide range of patients, including older patients with other medical co-morbidities."
The study reported on several planned subgroup analyses, including those with prior exposure to a covalent BTK inhibitor, those who had developed resistance to a covalent BTK inhibitor, and those who had TP53 aberration, which are all indicators of higher risk disease. Progression-free survival results were similar across subgroups.
"This study shows that pirtobrutinib can work even in the presence of covalent BTK inhibitor resistance mutations," says Davids. "Patients with high risk TP53 mutations also did well with the triplet regimen."
Prior to this study, the current standard second line therapy had only been evaluated in the phase 3 setting in a patient population predominantly treated with first-line chemoimmunotherapy, not the covalent BTK inhibitors used commonly as first-line therapy today. This shift raises questions about how well the current standard second line therapy is working in patients today. The control arm of the BRUIN CLL-322 study provides insights, showing shorter progression free survival in patients receiving current standard therapy after a BTK inhibitor compared to data from previous trials in patients receiving the current standard therapy after chemotherapy.
"This evidence aligns with what we have been observing in the clinic, which is that the current standard of care is not as effective in the modern patient population as it was in a more historical patient population," says Davids. "This new approach is an opportunity to add another drug to standard therapy to safely extend the duration of remission, and the time-limited nature of the regimen opens up the possibility of retreatment strategies in the future."
Funding: Eli Lilly and Company
***
Original text here: https://www.dana-farber.org/newsroom/news-releases/2026/fixed-duration-triplet-therapy-demonstrates-efficacy-for-patients-with-relapsedrefractory-cll
Five Baptist Memorial hospitals awarded 'A' Hospital Safety Grade
MEMPHIS, Tennessee, June 14 [Category: BizBizHospital] -- Baptist Memorial Health Care posted the following news release:
* * *
Five Baptist Memorial hospitals awarded 'A' Hospital Safety Grade
*
MEMPHIS, Tenn., June 14, 2026 - The Leapfrog Group, a nonprofit healthcare watchdog focused on patient safety, awarded "A" Hospital Safety Grades to five Baptist Memorial hospitals for their commitment to patient safety and quality care.
***
Original text here: https://www.baptistonline.org/news/five-baptist-memorial-hospitals-awarded-a-hospital-safety-grade/
AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal
MONROVIA, California, June 14 [Category: BizNational Defense] -- AeroVironment posted the following news release:
* * *
AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal
*
Lightweight un crewed ground vehicle expands mission flexibility for highly mobile units operating in complex and contested environments
OSTFILDERN, GERMANY -(June 15, 2026) -AeroVironment, Inc. ("AV"), a global leader in autonomous systems, today announced the launch of TOM 50 RE, a compact, backpackable uncrewed ground vehicle (UGV) developed by its wholly owned subsidiary
... Show Full Article
MONROVIA, California, June 14 [Category: BizNational Defense] -- AeroVironment posted the following news release:
* * *
AV Introduces TOM 50 RE, a Backpackable UGV for Rapid Reconnaissance and Explosive Ordnance Disposal
*
Lightweight un crewed ground vehicle expands mission flexibility for highly mobile units operating in complex and contested environments
OSTFILDERN, GERMANY -(June 15, 2026) -AeroVironment, Inc. ("AV"), a global leader in autonomous systems, today announced the launch of TOM 50 RE, a compact, backpackable uncrewed ground vehicle (UGV) developed by its wholly owned subsidiaryTelerob.
Designed for mobile exploration, mission-accompanying reconnaissance, explosive threat disposal, and operational support, TOM 50 RE enables dismounted forces, explosive ordnance disposal (EOD) teams, and special operations units-including SWAT-to rapidly deploy robotic capability wherever the mission demands.
The announcement was made at Eurosatory 2026, a global event for defence and security held in Paris.
"The introduction of TOM 50 RE reflects AV's commitment to delivering robotic systems that directly address the realities of modern ground combat and explosive threat environments," said Wahid Nawabi, Chairman, President, and Chief Executive Officer of AV. "Today's operators need systems that move with them, adapt to multiple missions, and provide immediate intelligence while reducing risk to human life. TOM 50 RE delivers that capability in a highly portable form factor built for the tactical edge."
Weighing less than 10 kilograms (22 pounds) and compact enough to be carried by a single operator, TOM 50 RE enables rapid deployment in confined and complex terrain, while its tracked design, stair-climbing flipper system, and dedicated mobility attachments allow it to overcome obstacles, navigate stairs and uneven terrain, and operate inside structures, delivering up to five hours of endurance and supporting payloads of up to five kilograms without compromising mobility.
With state-of-the-art onboard simultaneous localization and mapping (SLAM) capability, TOM 50 RE autonomously generates detailed maps of interior spaces, including multi-level buildings and global positioning system (GPS)-denied environments such as underground structures and dense urban terrain. Operators can identify and record points of interest directly within the digital map and export mission data immediately following operations, accelerating intelligence exploitation, supporting informed decision-making, and enabling more effective follow-on planning.
Equipped with four integrated high-resolution wide-angle cameras with infrared capability, TOM 50 RE delivers persistent 360-degree situational awareness in day, night, and degraded visual environments. Its advanced internet protocol (IP)-mesh radio architecture provides secure, resilient communications while enabling the system to function as a mobile repeater, extending connectivity for forces operating deep inside structures or complex terrain.
Its modular architecture, enabled by the Mission Module Interface (MMI) or an adapter supporting Telerob's Universal Component Interface (UCI), allows operators to integrate mission-specific payloads, including advanced camera systems and disruptors, and tailor the system to evolving operational requirements.
"TOM 50 RE was designed to deliver immediate robotic capability at the point of need, where operators face the greatest uncertainty and risk," said Florian Gruener, Managing Director of Telerob and Product Line General Manager for Uncrewed Ground Vehicles. "Its ability to rapidly conduct these missions in complex terrain allows forces to gain critical situational awareness, mitigate threats, and make faster, more informed decisions-while keeping personnel out of harm's way."
Controlled through AV _Halo(tm) COMMAND running on the Tomahawk Grip family of systems or the Robo Command Control System, operators can seamlessly manage TOM 50 RE alongside other uncrewed systems, enabling coordinated robotic operations and enhancing situational awareness across the mission.
The Four Missions
* For mobile exploration, TOM 50 RE provides immediate situational awareness in unknown or high-risk environments, allowing operators to scout structures, confined spaces, and urban terrain without exposing personnel to danger.
* In mission-accompanying reconnaissance, the system's integrated simultaneous localization and mapping (SLAM) capability enables it to navigate multi-story buildings, generate detailed interior maps, and identify and mark hazards or points of interest for follow-on forces.
* In defusing missions, TOM 50 RE supports the safe neutralization of improvised explosive devices and explosive hazards through modular disruptor and drop-charge payloads, allowing operators to mitigate threats from a safe distance.
* In its support role, in cooperation with the telemax EVO family of products, the system can serve as a mobile communications relay, extend operational reach, provide additional viewing angles, and enhance coordination between robotic and human elements across distributed teams.
TOM 50 RE expands AV's portfolio of intelligent, mission-ready ground robotic systems supporting defence, security, and public safety forces worldwide.
About AV
AV (NASDAQ: AVAV) is a defence technology leader delivering integrated capabilities across air, land, sea, space, and cyber. The Company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today's warfighter and tomorrow's conflicts. At the core of these technologies lies AV_Halo(tm), a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. For more information, visit www.avinc.com.
Safe Harbor Statement
Certain statements in this press release may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions that involve risks and uncertainties, which could cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, our ability to perform under existing contracts and obtain new ones; regulatory changes; competitor activities; market growth; product development challenges; and general economic conditions. For a more detailed discussion of these risks, please refer to AeroVironment's filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements as a result of new information or future events.
/////////////////////////////////////////////////////////////////////////////////////////////////////
For additional media and information, please follow us:
Media Contact:
BJ Koubaroulis
pr@avinc.com
703.718.4060
Investor Contact:
Denise Pacioni
ir@avinc.com
805.795.4108
***
Original text here: https://www.avinc.com/2026/06/14/av-introduces-tom-50-re-a-backpackable-ugv-for-rapid-reconnaissance-and-explosive-ordnance-disposal/
